BridgeBio Pharma (FRA:2CL) NonCurrent Deferred Liabilities: €763.8 Mil (As of Mar. 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
71 GF Score
Price €68.29
GF Value €111.53
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma NonCurrent Deferred Liabilities?

BridgeBio Pharma FRA:2CL +0.53% 71 NonCurrent Deferred Liabilities is €763.8 Mil as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 71/100 and a GF Value™ of €111.53 (Possible Value Trap). The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

BridgeBio Pharma's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €763.8 Mil.

BridgeBio Pharma NonCurrent Deferred Liabilities Related Terms

BridgeBio Pharma NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma NonCurrent Deferred Liabilities Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 3.42 473.86 741.37

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 476.20 718.42 723.57 741.37 763.76
FRA:2CL
71GF Score
BridgeBio Pharma Inc FRA:2CL
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €763.8 Mil mean?
BridgeBio Pharma (FRA:2CL) has a NonCurrent Deferred Liabilities of €763.8 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's NonCurrent Deferred Liabilities too high?
BridgeBio Pharma's current NonCurrent Deferred Liabilities is €763.8 Mil. Overall, BridgeBio Pharma has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's NonCurrent Deferred Liabilities compare to EXEL and IONS?
BridgeBio Pharma's NonCurrent Deferred Liabilities of €763.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current NonCurrent Deferred Liabilities is €763.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €111.53, compared to a current price of €68.29 — trading 38.8% below its estimated fair value. The current NonCurrent Deferred Liabilities is €763.8 Mil. BridgeBio Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current NonCurrent Deferred Liabilities is €763.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €68.29 is trading 38.8% below its estimated GF Value™ of €111.53. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • NonCurrent Deferred Liabilities: €763.8 Mil
  • GF Value™: €111.53 vs. price of €68.29 (38.8% below fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
71GF Score

Get the complete analysis for FRA:2CL

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.29
Price
€111.53
GF Value